Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
[primary effusion lymphoma]
Sphingosine
kinase
(
SPHK
)
is
overexpressed
by
a
variety
of
cancers
,
and
its
phosphorylation
of
sphingosine
results
in
accumulation
of
sphingosine-
1
-
phosphate
(
S
1
P
)
and
activation
of
antiapoptotic
signal
transduction
.
Existing
data
indicate
a
role
for
S
1
P
in
viral
pathogenesis
,
but
roles
for
SPHK
and
S
1
P
in
virus-associated
cancer
progression
have
not
been
defined
.
Rare
pathologic
variants
of
diffuse
large
B-
cell
lymphoma
arise
preferentially
in
the
setting
of
HIV
infection
,
including
primary
effusion
lymphoma
(
PEL
)
,
a
highly
mortal
tumor
etiologically
linked
to
the
Kaposi
's
sarcoma
-associated
herpesvirus
(
KSHV
)
.
We
have
found
that
ABC
294640
,
a
novel
clinical-grade
small
molecule
selectively
targeting
SPHK
(
SPHK
2
>
SPHK
1
)
,
induces
dose-dependent
caspase
cleavage
and
apoptosis
for
KSHV
(
+
)
patient-derived
PEL
cells
,
in
part
through
inhibition
of
constitutive
signal
transduction
associated
with
PEL
cell
proliferation
and
survival
.
These
results
were
validated
with
induction
of
PEL
cell
apoptosis
using
SPHK
2
-
specific
siRNA
,
as
well
as
confirmation
of
drug-induced
SPHK
inhibition
in
PEL
cells
with
dose-dependent
accumulation
of
proapoptotic
ceramides
and
reduction
of
intracellular
S
1
P
.
Furthermore
,
we
demonstrate
that
systemic
administration
of
ABC
294640
induces
tumor
regression
in
an
established
human
PEL
xenograft
model
.
Complimentary
ex
vivo
analyses
revealed
suppression
of
signal
transduction
and
increased
KSHV
lytic
gene
expression
within
drug-treated
tumors
,
with
the
latter
validated
in
vitro
through
demonstration
of
dose-dependent
viral
lytic
gene
expression
within
PEL
cells
exposed
to
ABC
294640
.
Collectively
,
these
results
implicate
interrelated
mechanisms
and
SPHK
2
inhibition
in
the
induction
of
PEL
cell
death
by
ABC
294640
and
rationalize
evaluation
of
ABC
294640
in
clinical
trials
for
the
treatment
of
KSHV-associated
lymphoma
.
Diseases
Validation
Diseases presenting
"pel cell proliferation"
symptom
primary effusion lymphoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom